triptorelin / Generic mfg. - LARVOL DELTA

The COSMYC Trial (COmbined Suppression of MYC) (clinicaltrials.gov) - P2 | N=50 | Not yet recruiting | Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

New P2 trial • Castration-Resistant Prostate Cancer • CNS Disorders • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Diagnosis Prostate Cancer via Molecular Computed Tomography Imaging based on Targeted Gold Nanoparticles. (PubMed, Cell J) - "The current study demonstrates that synthesized TAuNPs are emerged as a contrast agent, which is targeted for molecular CT imaging of prostate cancer cells, expressing the gonadotropin-releasing hormone (GnRH) receptor."

Journal • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Comparison of Cardiovascular Events in Patients with Advanced Prostate Cancer treated with Luteinizing Hormone Releasing Hormone Agonists versus Antagonists in the US: An Analysis of the TriNetX Database (AUA 2025) - "INTRODUCTION AND OBJECTIVE: The standard of care for metastatic castrate-sensitive prostate cancer (mCSPCa) is the androgen deprivation therapy (ADT) using LHRH agonists (LHRH-A: leuprolide, goserelin or triptorelin) or LHRH antagonists (LHRH-An: degarelix or relugolix). In a real-world, multi-center cohort, patients receiving LHRH agonists as compared to LHRH antagonists were found to be at 1.38 times higher risk of experiencing a major adverse cardiovascular event and 2.36 times higher risk of stroke. These data support the potential use of LHRH antagonists preferentially in at-risk patients while prospective data is awaited."

Clinical • Metastases • Cardiovascular • Cerebral Hemorrhage • Genito-urinary Cancer • Hematological Disorders • Myocardial Infarction • Oncology • Prostate Cancer • Solid Tumor

Study of persistence and adherence to ADT in prostate cancer: relugolix, degarelix, and GnRH agonists in the US. (PubMed, Future Oncol) - "This retrospective study evaluates persistence and adherence of relugolix, degarelix, and GnRH agonists (leuprolide, goserelin, triptorelin, histrelin) using data from the IBM MarketScan Research Database (Jan 2017 - Dec 2022). Persistence and adherence rates were higher in metastatic prostate cancer. Findings support relugolix use as an oral treatment due to its favorable persistence and long-term adherence profiles."

Journal • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

IMPACT ON FERTILITY AND BONE MASS OF TRIPTORELIN AND ESTRADIOL THERAPY IN TRANS GIRLS (ESPE-ESE 2025) - No abstract available

A single-center experience of the effect of triptorelin on final height in girls with precocious or early puberty (ESPE-ESE 2025) - No abstract available

Clinical

Transient arterial hypertension developed during therapy with triptorelin in a girl with central precocious puberty. (ESPE-ESE 2025) - No abstract available

Cardiovascular • Endocrine Disorders • Pulmonary Arterial Hypertension

Triptorelin stimulated gonadotropin concentrations for precocious puberty (ESPE-ESE 2025) - No abstract available

Triptorelin Effects on Linear Growth and Bone Mineral Density in Transgender Adolescents: A Longitudinal Study (ESPE-ESE 2025) - No abstract available

Longitudinal study • Observational data

ADY: FET in Adenomyosis (clinicaltrials.gov) - P=N/A | N=700 | Not yet recruiting | Sponsor: Indira IVF Hospital Pvt Ltd

New trial • Endometriosis • Women's Health

Study on the pharmacokinetics of A05 for injection (ChiCTR) - P=N/A | N=12 | Recruiting | Sponsor: Yuncheng Central Hospital; Yuncheng Central Hospital

New trial • Breast Cancer • Endocrine Disorders • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

A multice-center, prospective study on the diagnostic value of triptorelin provocation test for central precocious puberty in girls with different BMI. (ChiCTR) - P4 | N=0 | Recruiting | Sponsor: children's hospital of fudan university; children's hospital of fudan university

New P4 trial • Endocrine Disorders

Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial (clinicaltrials.gov) - P3 | N=2050 | Recruiting | Sponsor: NRG Oncology | Trial completion date: Apr 2037 ➔ Nov 2026 | Trial primary completion date: Apr 2032 ➔ Nov 2026

Trial completion date • Trial primary completion date • Genito-urinary Cancer • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor

SOFT: Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer (clinicaltrials.gov) - P3 | N=3066 | Completed | Sponsor: ETOP IBCSG Partners Foundation | Active, not recruiting ➔ Completed | Trial completion date: Dec 2025 ➔ Nov 2024 | Trial primary completion date: May 2014 ➔ Nov 2024

Trial completion • Trial completion date • Trial primary completion date • Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • ER • PGR

High-Dose Brachytherapy in Treating Patients With Prostate Cancer (clinicaltrials.gov) - P=N/A | N=146 | Active, not recruiting | Sponsor: Stanford University | Trial completion date: Dec 2026 ➔ May 2026

Trial completion date • Genito-urinary Cancer • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor

In vitro study of effect of gold nanoparticles conjugated with triptorelin peptide on the radiosensitivity of breast cancer cells (MCF-7). (PubMed, Discov Oncol) - "The results of the tests showed that Triptorelin-AuNPs nanoparticles have the ability to cause targeted sensitivity in MCF-7 cells with triptorelin peptide receptors."

Journal • Preclinical • Breast Cancer • Oncology • Solid Tumor • ANXA5

TEXT: Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer (clinicaltrials.gov) - P3 | N=2672 | Completed | Sponsor: ETOP IBCSG Partners Foundation | Active, not recruiting ➔ Completed | Trial completion date: Dec 2025 ➔ Oct 2024

Trial completion • Trial completion date • Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Inflammatory Breast Cancer • Oncology • Solid Tumor • Thyroid Gland Carcinoma • PGR

Knight Therapeutics Reports Fourth Quarter and Year-End 2024 Results (GlobeNewswire) - "For the quarter ended December 31, 2024...Revenues from our key promoted products increased by $5,781 or 42% on a constant currency basis driven by the growth of Lenvima, Akynzeo, Trelstar and the launch of Minjuvi in Brazil...For the year ended December 31, 2024, the oncology/hematology portfolio increased by $26,211 or 23% of which $11,336 is due to the Hyperinflation Impact1. Excluding IAS 29, the oncology/hematology portfolio increased by $14,875 or 12%. Our key promoted brands grew by $23,831 or 49% on a constant currency2 basis driven by the growth of Lenvima, Akynzeo, Trelstar and the launch of Minjuvi in Brazil."

Commercial • Breast Cancer • Diffuse Large B Cell Lymphoma • Endocrine Cancer • Endometrial Cancer • Hepatocellular Cancer • Prostate Cancer • Renal Cell Carcinoma • Thyroid Gland Carcinoma • Urothelial Cancer • Uterine Cancer • Uterine Leiomyoma

Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer (clinicaltrials.gov) - P2 | N=25 | Recruiting | Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Trial completion date: Dec 2027 ➔ Jan 2027 | Trial primary completion date: Dec 2027 ➔ Jan 2027

Trial completion date • Trial primary completion date • Castration-Sensitive Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Adolescent Gender Dysphoria in Italy: Reflections on Triptorelin, Consent, and Care. (PubMed, Clin Ter) - "This paper advocates for a hybrid approach, integrating strengths of both models to ensure safe, accessible, and individualized care. Further research is essential to clarify the efficacy and risks of triptorelin, ensuring evidence-based, fully informed decisions for adolescents with GD."

Journal • Review • CNS Disorders • Psychiatry

Comparing IVF/ICSI Cycle Outcomes of Post Ovulation Ovarian Stimulation Protocol with Elonva Without GnRH Antagonist to Follicular Phase Day 2 Stimulation Fixed Day 5 Antagonist Protocol (clinicaltrials.gov) - P=N/A | N=252 | Not yet recruiting | Sponsor: ART Fertility Clinics LLC

New trial

An Unusual Presentation of Costello Syndrome in a Boy with Precocious Puberty and Chiari I Malformation: A Case Report. (PubMed, Cureus) - "At nine years and eight months, triptorelin treatment was initiated, leading to a reduction of pubic hair, stabilization of testicular volume, and a stature of -1.64 SD at the age of 13 years. Despite known factors influencing puberty, the precise physiological mechanisms behind its initiation remain unclear. This case provides valuable insights for understanding the genotype-phenotype relationship in Costello syndrome."

Journal • Developmental Disorders • Endocrine Disorders • Genetic Disorders • Oncology • Pediatrics • Solid Tumor • HRAS

GO39932: A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer (clinicaltrials.gov) - P1 | N=181 | Active, not recruiting | Sponsor: Genentech, Inc. | Trial completion date: Jun 2025 ➔ Jun 2026 | Trial primary completion date: Jun 2025 ➔ Jun 2026

Trial completion date • Trial primary completion date • Breast Cancer • Estrogen Receptor Positive Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • ER • HER-2

A 6-month sustained-release formulation of triptorelin for locally advanced or metastatic prostate cancer: a real-world experience in Asia. (PubMed, BMC Urol) - "The LAT adherence rate was high in the setting of hormonal treatment for prostate cancer. Testosterone suppression was satisfactory after the initiation of LAT and was generally well tolerated."

Journal • Real-world evidence • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Efficacy of Triptorelin Combined with Recombinant Human Growth Hormone (rhGH) on Serum Sex Hormones, Bone Age, and Clinical Outcomes in Girls with Precocious Puberty. (PubMed, Br J Hosp Med (Lond)) - "No serious adverse reactions were observed in either group during the treatment period. Conclusion The combination of triptorelin and rhGH demonstrates a clear therapeutic in girls with precocious puberty, which effectively delays bone age growth, regulates sex hormone levels, and reduces ovarian and uterine volumes without severe adverse effects."

Clinical data • Journal • Retrospective data